BackReviva Pharmaceuticals Holdings Overview

Reviva Pharmaceuticals Holdings Net Tangible Assets

Latest net tangible assets for RVPH: $15T.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$15207.25B
3312064645.78% YoYΔ $15207.25B vs prior year quarter

Peer trimmed avg / median

Loading

Reviva Pharmaceuticals Holdings Net Tangible Assets History

Loading

Reviva Pharmaceuticals Holdings vs. peers: Net Tangible Assets Comparison

Loading

Reviva Pharmaceuticals Holdings Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Reviva Pharmaceuticals Holdings (RVPH) FAQ

Reviva Pharmaceuticals Holdings's net tangible assets stands at $15T as of June 2026. That compares with $-460K in the prior-year period — up 3312064645.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Reviva Pharmaceuticals Holdings reported $15T in net tangible assets versus $-460K a year earlier — a 3312064645.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-460K in the prior-year period — up 3312064645.8% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Reviva Pharmaceuticals Holdings's net tangible assets evolved across reporting periods, while the comparison chart places RVPH next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Reviva Pharmaceuticals Holdings's reading of $15T is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.